MRK vs NVO

Merck & Co. and Novo Nordisk A/S, both Healthcare

Merck & Co. is the larger company at $281B against $191B. Over the past year MRK returned +99% against +1.5% for NVO. Ryufin's sector-relative Smart Score puts NVO ahead, 9/10 against 8/10.

Merck & Co. and Novo Nordisk A/Scompared on valuation, return and Ryufin’s Smart Score
Figure	MRK	NVO
Last close	$153	$47.19
Market cap	$281B	$191B
Trailing P/Elower is cheaper for the same earnings, not automatically better	121.6	n/a
Dividend yield	2.1%	n/a
1-year return	+99%	+1.5%
5-year return	+133%	+13%
Ryufin Smart Scoresector-relative, 1–10	8/10	9/10

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Merck & Co.

Revenue of $17B in Q2 2026, net income null. Its largest reported line is Keytruda, 49% of the disclosed total.

MRK overview revenue and segments valuation

Novo Nordisk A/S

NVO overview revenue and segments valuation

Open these two in the interactive comparison to add more names, change the period or read the correlation.